felin
infecti
periton
viru
fipv
major
pathogen
felida
despit
extens
effort
taken
past
decad
develop
ideal
live
attenu
fipv
vaccin
success
yet
present
studi
provid
data
immunis
experi
recombin
fcov
pair
differ
truncat
complet
region
previou
vivo
studi
virus
prove
show
charact
low
virul
avirul
fcov
phenotyp
respect
therefor
hypothesis
abil
virus
possibl
vaccin
candid
confer
protect
specif
pathogen
free
spf
domest
shorthair
well
convent
purebr
british
shorthair
cat
spf
cat
two
oronas
two
intramuscular
vaccin
two
week
interv
vaccin
candid
provid
protect
lethal
homolog
challeng
highli
virul
fipv
strain
contrast
convent
purebr
british
shorthair
cat
develop
protect
immunis
vaccin
regim
group
immunis
anim
develop
antibodydepend
enhanc
ade
prolong
surviv
observ
anim
show
fulmin
diseas
cours
genet
probabl
immunolog
differ
spf
nonspf
purebr
kitten
explain
differ
outcom
vaccin
experi
data
highlight
divers
immun
respons
spf
convent
cat
suggest
decis
role
previou
infect
heterolog
caus
agent
outcom
vaccin
fip
author
publish
elsevi
bv
fcov
probabl
emerg
via
doubl
recombin
process
type
fcov
type
ii
canin
coronaviru
ccov
herrewegh
et
al
serotyp
occur
two
pathotyp
felin
enter
coronaviru
fecv
replic
lower
portion
intestin
tract
spread
faecalor
rout
clinic
appear
characteris
mild
unappar
enter
pedersen
et
al
herrewegh
et
al
contrast
felin
infecti
periton
viru
fipv
effici
replic
macrophag
monocyt
occur
sporad
caus
highli
lethal
system
granulomat
diseas
felin
infecti
periton
fip
manifest
either
wet
dri
form
addi
jarrett
de
grootmijn
et
al
although
extens
effort
taken
past
decad
develop
ideal
live
attenu
fipv
vaccin
replic
bodi
without
clinic
sign
induc
protect
immun
fipv
pedersen
crown
complet
success
yet
vaccin
close
relat
heterolog
live
cov
confer
protect
barlough
et
al
barlough
et
al
stoddart
et
al
wood
pedersen
similarli
inactiv
recombin
fcov
subunit
vaccin
review
haijema
et
al
immunis
fecv
lowvirul
fipv
subleth
amount
virul
fipv
elicit
partial
protect
pedersen
black
pedersen
et
al
pedersen
floyd
frequent
lead
antibodi
enhanc
diseas
ade
socal
earli
death
syndrom
current
temperaturesensit
strain
fipv
market
worldwid
abil
protect
cat
fipv
gerber
et
al
gerber
efficaci
uncertain
mcardl
et
al
scott
et
al
fehr
et
al
promis
result
obtain
recombin
fipv
mutant
lack
region
provid
protect
lethal
homolog
challeng
haijema
et
al
respect
howev
followup
studi
use
vaccin
candid
publish
far
present
studi
provid
data
immunis
experi
recombin
fcov
pair
differ
truncat
intact
region
lint
et
al
previou
vivo
studi
use
specif
pathogen
free
spf
cat
prove
low
virul
shed
limit
titr
faec
complet
clear
immun
system
elicit
medium
level
immun
respons
show
activ
intestin
replic
faecal
shed
possess
complet
avirul
phenotyp
lint
et
al
consid
advantag
characterist
two
recombin
fcov
evalu
innocu
efficaci
vaccin
candid
confer
protect
spf
well
convent
purebr
british
shorthair
cat
feli
catu
whole
foetu
cell
use
viru
propag
titrat
viru
neutralis
test
cell
line
maintain
monolay
cultur
dulbecco
modifi
eagl
medium
sigmaaldrich
saint
loui
mo
usa
supplement
foetal
bovin
serum
fb
mgml
glutamin
uml
penicillin
mgml
streptomycin
mgml
amphotericin
b
mm
sodium
pyruv
nonessenti
amino
acid
sigmaaldrich
fipv
strain
kindli
provid
berndt
klingeborn
sva
uppsala
sweden
whole
genom
fipv
clone
pbelobac
lowcopi
vector
allow
effici
intracellular
product
viral
rna
cdna
cytomegaloviru
cmv
immediateearli
promot
order
gain
recombin
fcov
genbank
access
number
origin
truncat
viru
replac
intact
type
fcovlik
canin
coronaviru
ccov
refer
strain
construct
genbank
access
number
lint
et
al
spf
domest
shorthair
iqhsdcpb
kitten
isoquimen
sl
barcelona
spain
convent
british
shorthair
cat
fcov
neg
hungarian
catteri
regularli
monitor
two
gener
use
challeng
experi
nonspf
cat
origin
three
nonrel
queen
two
tom
kitten
arriv
facil
age
week
acclim
use
studi
age
week
anim
kept
separ
group
close
facil
fcov
neg
statu
check
pcr
viru
neutralis
test
absenc
felin
parvoviru
fpv
felin
herpesviru
fhv
felin
caliciviru
fcv
felin
immunodefici
viru
fiv
felin
leukaemia
viru
felv
convent
cat
confirm
pcr
andor
elisa
test
studi
purpos
group
structur
establish
spf
convent
kitten
two
studi
group
group
group
n
control
group
cgroup
n
form
kitten
inocul
oronas
intramuscularli
tissu
cultur
infect
dose
tcid
recombin
virus
group
group
respect
vaccin
anim
unvaccin
control
oronas
challeng
tcid
parent
viru
fipv
whole
clinic
observ
period
time
altogeth
month
long
time
kitten
clinic
examin
daili
basi
cat
score
sever
clinic
sign
describ
earlier
haijema
et
al
briefli
score
base
depress
inact
three
consecut
day
point
anorexia
eat
three
consecut
day
point
neurolog
disord
swagger
point
daili
basi
fever
point
jaundic
yellow
plasma
point
weight
loss
loss
bodi
weight
per
week
point
lymphopenia
lymphocyt
count
l
score
weekli
basi
kitten
show
sign
termin
fip
euthan
order
avoid
unnecessari
suffer
healthi
anim
extermin
day
postchalleng
pc
follow
full
postmortem
examin
anim
experi
approv
supervis
ethic
anim
welfar
committe
nation
food
chain
safeti
offic
anim
die
euthan
experi
subject
patholog
examin
carcass
dissect
within
two
hour
death
sampl
taken
spleen
kidney
liver
lung
brain
intestin
fix
formaldehyd
embed
paraffin
wax
block
section
mm
section
stain
haematoxylineosin
examin
light
microscop
determin
viru
shed
faecal
oropharyng
swab
taken
place
ml
phosphat
buffer
salin
pb
vortex
min
incub
swab
remov
extract
centrifug
g
min
remov
cell
debri
supernat
collect
use
subsequ
pcr
viral
rna
purifi
use
qiaamp
viral
rna
mini
kit
qiagen
hilden
germani
measur
copi
number
genom
recombin
fcov
taqman
assay
target
end
fipv
genom
appli
lint
et
al
serum
sampl
taken
use
vacuett
tube
greiner
bioon
germani
day
faecal
sampl
viru
neutralis
vn
assay
twofold
dilut
heatinactiv
serum
kitten
ml
incub
h
equal
aliquot
fipv
ml
tcid
ml
virus
ad
cell
show
confluenc
plate
incub
h
develop
cytopath
effect
neutralis
activ
determin
endpoint
dilut
shiba
et
al
studi
whether
inocul
would
protect
cat
homolog
fipv
challeng
vaccin
challeng
experi
perform
group
group
cat
vaccin
oronas
twice
tcid
respect
vivo
characterist
recombin
virus
similar
earlier
experi
lint
et
al
cat
group
show
earli
mild
clinic
sign
includ
transient
fever
anorexia
slight
lymphopenia
tabl
cat
group
show
neither
clinic
sign
typic
fip
diarrhoea
tabl
oropharyng
shed
either
detect
whole
period
immunis
experi
data
shown
shed
faec
group
detect
four
anim
variabl
amount
close
detect
limit
genom
quantit
rtpcr
fcov
rna
copi
per
ml
faecal
extract
fig
group
cat
began
shed
viru
shed
peak
fcov
rna
copi
per
ml
faecal
extract
remain
high
began
decreas
reach
fcov
rna
copi
per
ml
faecal
extract
remain
level
end
experi
fig
neutralis
activ
detect
cat
sera
contrast
group
cat
seroconvert
show
medium
titr
neutralis
antibodi
fig
group
cat
show
tabl
total
clinic
score
spf
cat
oronas
parenter
day
vaccin
pbfipv
group
n
group
n
unvaccin
control
cgroup
n
vaccin
pb
viru
anim
three
anim
seroconvert
vn
titr
remain
low
level
compar
group
cat
fig
sinc
level
humor
immun
respons
oronas
vaccin
recombin
virus
rel
low
two
intramuscular
vaccin
tcid
appli
control
group
cgroup
mock
vaccin
pb
similarli
oronas
vaccin
intramuscularli
inocul
kitten
develop
sign
fip
tabl
faecal
viru
shed
group
cat
detect
faecal
shed
group
kitten
continu
low
level
fig
oropharyng
shed
observ
anim
two
vaccin
group
data
shown
neutralis
antibodi
titr
rais
group
anim
intramuscular
vaccin
p
interestingli
one
group
anim
seroconvert
titr
significantli
rais
p
somewhat
lower
antibodi
valu
obtain
four
group
anim
compar
group
p
fig
kitten
challeng
oronas
tcid
virul
fipv
strain
monitor
month
cgroup
cat
show
sever
clinic
sign
fip
start
second
week
tabl
two
kitten
die
day
postchalleng
pc
patholog
histopatholog
examin
reveal
lesion
characterist
system
noneffus
fip
contrari
vaccin
prove
highli
efficaci
lethal
fipv
challeng
group
group
cat
remain
healthi
tabl
surviv
least
month
vn
titr
boost
significantli
tabl
total
clinic
score
pbfipv
n
n
vaccin
spf
cat
challeng
fipv
n
studi
efficaci
vaccin
candid
field
condit
experi
protocol
repeat
use
convent
cat
neither
vaccin
kitten
show
sign
fatal
fip
tabl
group
inocul
anim
show
slightli
stronger
clinic
sign
spf
counterpart
includ
lymphopenia
characterist
sign
earli
fipv
infect
anorexia
observ
two
group
kitten
tabl
oropharyng
viru
shed
detect
vaccin
cat
data
shown
faecal
viru
shed
convent
cat
approxim
log
higher
intens
longer
durat
day
extend
pbfipv
inocul
anim
compar
spf
anim
fig
neutralis
antibodi
induc
anim
show
approxim
one
log
higher
titr
observ
spf
anim
fig
challeng
control
cat
show
clinic
sign
fip
follow
death
day
pc
similarli
spf
anim
slightli
faster
develop
diseas
earlier
death
tabl
patholog
find
characterist
system
noneffus
fip
vaccin
show
variabl
result
lethal
fipv
challeng
two
group
cat
cat
cat
slightli
higher
vn
antibodi
titr
fig
develop
fip
later
day
pc
die
day
tabl
total
clinic
score
convent
cat
oronas
parenter
day
vaccin
pbfipv
group
n
group
n
unvaccin
control
cgroup
n
vaccin
pb
viru
anim
tabl
total
clinic
score
pbfipv
group
n
group
n
pb
cgroup
n
vaccin
convent
cat
challeng
fipv
n
group
cgroup
pc
respect
postmortem
examin
reveal
characterist
fip
lesion
similar
observ
fulmin
cours
diseas
three
cat
group
develop
fip
within
week
tabl
follow
death
day
pc
fulmin
cours
diseas
major
vaccin
anim
suggest
least
partial
advers
effect
vaccin
instead
protect
group
anim
develop
fip
within
week
tabl
follow
death
day
pc
exclus
fulmin
cours
diseas
also
indic
clear
advers
characterist
vaccin
candid
perish
anim
show
fulmin
fip
vn
titr
elev
rapidli
death
fig
number
scientif
data
indic
fip
consequ
recent
interspeci
jump
coronaviru
consid
fact
diseas
seen
review
pedersen
immunolog
aspect
fip
complex
fulli
elucid
yet
fipv
could
neg
influenc
immun
system
interven
sever
point
viru
variant
highli
virul
monocytemacrophag
pathogen
caus
system
immun
complex
mediat
infect
vennema
et
al
takano
et
al
chang
et
al
fact
may
explain
acquir
natur
immun
cat
rather
limit
fipv
also
efficaci
vaccin
avail
fipv
despit
intens
effort
academ
commerci
research
studi
vaccin
regim
appli
spf
convent
purebr
british
shorthair
cat
use
recombin
fcov
pair
differ
truncat
intact
region
vivo
evalu
viru
pair
show
virus
possess
low
virul
avirul
phenotyp
respect
lint
et
al
low
inconsist
level
faecal
shed
observ
present
experi
follow
vaccin
recombin
similar
observ
infect
truncat
fcov
chang
et
al
pedersen
et
al
seroconvers
reach
medium
level
two
oronas
vaccin
gradual
elev
two
intramuscular
inject
absenc
antibodi
enhanc
ade
lead
fip
strong
antibodi
respons
induc
group
complet
vaccin
regim
howev
high
booster
effect
observ
four
individu
inocul
reach
higher
antibodi
titr
elicit
signific
booster
effect
modif
vaccin
protocol
experi
might
requir
vaccin
caus
low
level
lymphopenia
prove
transient
follow
second
wave
signific
lymphoid
cell
decreas
characterist
cours
fatal
fip
togeth
lack
advers
clinic
sign
advantag
develop
safe
vaccin
vaccin
clinic
sign
observ
confirm
avirul
phenotyp
fecv
characterist
recombin
fcov
faecal
viru
shed
higher
detect
prolong
period
compar
phenomenon
accord
previou
find
intact
region
indispens
enter
replic
fcov
chang
et
al
pedersen
et
al
lint
et
al
high
mutat
frequenc
recombin
common
featur
coronavirus
lead
increas
virul
attenu
strain
use
vaccin
reason
longer
persist
shed
inocul
make
less
favour
vaccin
candid
low
inconsist
antibodi
respons
observ
subsequ
two
oronas
vaccin
antibodi
level
significantli
increas
intramuscular
inocul
level
compar
clearli
lower
vaccin
anim
low
inconsist
initi
antibodi
respons
may
consequ
intact
direct
fcov
replic
enterocyt
restrict
macrophag
lint
et
al
case
spf
cat
recombin
fcov
truncat
complement
protect
vaccin
anim
homolog
challeng
highli
lethal
fipv
strain
antibodi
titr
anim
increas
significantli
challeng
show
absenc
uncontrol
fipv
replic
nonspf
spf
cat
react
physiolog
similarli
ident
vaccin
regim
although
clinic
paramet
fever
depress
anorexia
nonspf
anim
somewhat
differ
observ
spf
cat
viru
shed
serolog
respons
level
also
slightli
higher
indic
intens
viru
replic
immun
reaction
howev
strike
differ
two
experi
vaccin
candid
provid
far
less
protect
purebr
cat
challeng
fipv
strain
case
challeng
led
ade
case
develop
sever
symptom
fip
nonspf
anim
independ
genet
characterist
appli
vaccin
candid
ade
pathomechan
exclus
featur
fipv
infect
resembl
adebas
dengu
haemorrhag
shock
syndrom
first
describ
peiri
porterfield
phenomenon
also
observ
case
flavivirus
alphavirus
lentivirus
influenzavirus
enterovirus
measl
viru
peiri
porterfield
porterfield
takeda
et
al
tamura
et
al
chen
et
al
iankov
et
al
suspect
ade
might
sever
earli
fipv
challeng
vaccin
howev
lack
develop
fatal
fip
ade
among
spf
cat
prolong
surviv
two
nonspf
anim
day
challeng
suggest
biolog
factor
could
strong
effect
develop
fip
earli
challeng
two
vaccin
anim
origin
differ
litter
common
father
remain
symptomless
week
surviv
time
prolong
usual
week
day
fipv
challeng
rather
unusu
infect
cours
diseas
clearli
differ
ade
resembl
latent
sequest
infect
fipv
reactiv
immunosuppress
agent
felv
pedersen
previou
pilot
vaccin
trial
use
differ
dna
immun
stimul
complex
iscom
vaccin
candid
harbour
n
genesprotein
spf
n
convent
cat
n
appli
fipv
challeng
strain
control
vaccin
anim
perish
within
four
week
without
sign
ade
farsang
et
al
unpublish
result
studi
conduct
other
congruent
indic
virtual
cat
develop
fip
within
four
week
fipv
challeng
review
pedersen
first
case
observ
longterm
surviv
vaccin
trial
may
consequ
either
slightli
higher
neutralis
antibodi
titr
two
anim
result
alter
specif
immun
respons
prolong
surviv
vaccin
cat
make
promis
candid
vaccin
develop
genet
immunolog
differ
spf
nonspf
purebr
kitten
explain
differ
outcom
vaccin
experi
although
frequent
occurr
fip
report
australia
certain
breed
includ
british
shorthair
domest
shorthair
cat
norri
et
al
yet
signific
influenc
genet
background
anim
less
like
abl
find
surviv
neither
among
domest
shorthair
cat
control
present
experi
among
vaccin
domest
shorthair
cat
earlier
iscom
dna
vaccin
trial
fipv
challeng
vaccin
trial
reveal
subneutralis
level
spike
proteinspecif
antibodi
lead
ade
facilit
fc
receptormedi
uptak
fcov
macrophagesmonocyt
contribut
develop
earli
death
syndrom
weiss
scott
vennema
et
al
corapi
et
al
hohdatsu
et
al
olsen
et
al
vaccin
british
shorthair
cat
result
heterolog
immunolog
respons
surviv
time
despit
common
genet
background
fact
also
suggest
immun
statu
substanti
role
develop
diseas
cours
vaccin
genet
background
spf
kitten
bred
isol
circumst
neither
meet
rang
pathogen
nonpathogen
parasit
bacteria
fungi
virus
take
matern
antibodi
colostrum
nonspf
anim
kept
even
best
circumst
encount
microorgan
convent
purebr
british
shorthair
cat
develop
higher
vn
antibodi
titr
antibodi
particular
fraction
might
led
observ
ade
although
direct
connect
felin
bacteri
flora
viru
neutralis
titr
publish
far
abund
scientif
data
confirm
direct
indirect
influenc
microbiota
composit
outcom
pathogen
infect
slifka
et
al
teixeira
et
al
wilk
golovkina
presenc
intestin
microb
directli
facilit
infect
reovirus
poliovirus
vitro
vivo
kuss
et
al
bacteri
flora
promot
matur
secondari
lymphoid
organ
intestin
lee
mazmanian
influenc
gene
express
antigenpres
cell
way
cell
respond
vaccin
klaasen
et
al
smith
et
al
furthermor
interact
macrophag
probiot
bacteria
lead
increas
antivir
respons
vesicular
stomat
viru
vitro
ivec
et
al
sinc
fip
result
type
iii
iv
hypersensit
reaction
pedersen
boyl
paltrinieri
et
al
tempt
specul
matur
immun
system
nonspf
cat
predispos
anim
develop
diseas
summari
vaccin
experi
show
hyperimmunis
spf
cat
low
virul
recombin
fcov
confer
complet
protect
lethal
homolog
challeng
howev
partial
protect
observ
use
vaccin
protocol
nonspf
cat
data
highlight
divers
immun
respons
spf
convent
cat
suggest
decis
role
previou
infect
heterolog
caus
agent
outcom
vaccin
fip
author
disclos
financi
person
relationship
peopl
organis
could
inappropri
influenc
bia
work
research
grant
agria
anim
insur
compani
agria
kring
swedish
kennel
club
svenska
kennelklubben
skk
otka
nkth
otka
no
lyai
fellowship
hungarian
academi
scienc
